No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
STTK240517C7500
- 3.03
- +0.03+1.00%
15min DelayClose May 10 15:59 ET
3.03High3.03Low
3.03Open3.00Pre Close1 Volume25 Open Interest7.50Strike Price303.00Turnover218.75%IV1.25%PremiumMay 17, 2024Expiry Date2.92Intrinsic Value100Multiplier5DDays to Expiry0.11Time Value100Contract SizeAmericanOptions Type0.9137Delta0.0564Gamma3.42Leverage Ratio-0.0399Theta0.0010Rho3.12Eff Leverage0.0020Vega
Intraday
- 5D
- 1D
News
Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
Buy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154
Express News | HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $28 Price Target
Shattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical Milestones
Express News | Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Comments
$Shattuck Labs(STTK.US$
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
1
$Shattuck Labs(STTK.US$ Shattuck Labs Announces Drug Discovery Collaboration With Ono Pharmaceutical, For Bifunctional Fusion Proteins Targeting Certain Autoimmune And Inflammatory Disease Pathways, Shattuck To Receive Upfront And Be Eligible For Milestone Payments Of Upto $227M
$Shattuck Labs(STTK.US$ 7.50 after hours 🚀🚀🚀🚀
$Shattuck Labs(STTK.US$ 8.00 now 🚀🚀🚀🚁
Read more